Referencias:
1. Muneer A. Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update. Clin Psychopharmacol Neurosci 2015;13(1):25-35. 2. Vieta E, Berk M, Schulze TG et al. Bipolar disorders. Nat Rev Dis Primers 2018;4:18008. 3. Información para prescribir amplia. Seroquel (quetiapina). Reg. No. 071M98 SSA IV. México 2018. 4. Información para prescribir amplia. Seroquel XR (quetiapina liberación prolongada). Reg. No. 113M2012 SSA IV. México 2018. 5. Ketter TA, Miller S, Dell’Osso B et al. Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. J Affect Disord 2016;191:256-273. 6. Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20(2):97-170. 7. Samalin L, Tremey A, Llorca PM. Quetiapine extended release for the treatment of bipolar disorder. Expert Rev Neurother 2014;14(9):987-1005. 8. Enríquez-Sánchez H, Ochoa-Madrigal MG. Espectro de la esquizofrenia en niños y adolescentes. Revista de la Facultad de Medicina de la UNAM 2019;62(4):9-23. 9. Shoja Shafti S, Kaviani H. Quetiapine versus aripiprazole in the management of schizophrenia. Ther Adv Psychopharmacol 2015;5(3):166-171. 10. Wang C, Shi W, Huang C et al. The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial. Ann Gen Psychiatry 2017;16:47. 11. Maneeton N, Maneeton B, Woottiluk P et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2016;10:259-276. 12. Ignacio ZM, Calixto AV, da Silva RH et al. The use of quetiapine in the treatment of major de- pressive disorder: Evidence from clinical and experimental studies. Neurosci Biobehav Rev 2018;86:36-50.